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Abstract: Coenzyme Q10 (CoQ10) is an essential cofactor in the mitochondrial respiratory 
chain, and as a dietary supplement it has recently gained attention for its potential role in the treat-
ment of neurodegenerative disease. Evidence for mitochondrial dysfunction in neurodegenerative 
disorders derives from animal models, studies of mitochondria from patients, identification 
of genetic defects in patients with neurodegenerative disease, and measurements of markers 
of oxidative stress. Studies of in vitro models of neuronal toxicity and animal models of 
neurodegenerative disorders have demonstrated potential neuroprotective effects of CoQ10. With 
this data in mind, several clinical trials of CoQ10 have been performed in Parkinson’s disease 
and atypical Parkinson’s syndromes, Huntington’s disease, Alzheimer disease, Friedreich’s 
ataxia, and amyotrophic lateral sclerosis, with equivocal findings. CoQ10 is widely available 
in multiple formulations and is very well tolerated with minimal adverse effects, making it an 
attractive potential therapy. Phase III trials of high-dose CoQ10 in large sample sizes are needed 
to further ascertain the effects of CoQ10 in neurodegenerative diseases.
Keywords: coenzyme Q10, neurodegenerative disease, Parkinson’s disease, Huntington’s 
disease, mitochondrial dysfunction
Introduction
Over the past decade, interest in the roles of nutritional supplements in 
neurodegenerative disease has intensified. One of  these supplements, coenzyme Q10 
(CoQ10), is an essential cofactor involved in mitochondrial oxidative phosphoryla-
tion as well as a potent antioxidant. Strong evidence has now emerged supporting 
the role of oxidative stress and defective energy metabolism in the pathogenesis of 
many neurodegenerative disorders, such as Parkinson’s disease (PD), Huntington’s 
disease (HD), and Alzheimer disease (AD). There is, therefore, a robust scientific 
rationale for testing this agent as a potential neuroprotective therapy. Levels of 
CoQ10 in the brain and other tissues in humans and animals have been shown 
to decline with age, further suggesting a potential therapeutic role in age-related 
neurodegenerative disorders.1–3 Moreover, the substantia nigra, in which cell death 
results in the disabling motor symptoms of PD, has the lowest CoQ10 content within 
the brain.4 In light of these findings, in recent years a series of clinical trials have 
been undertaken in order to test CoQ10 effects in neurodegenerative disease. Here 
we review the most important clinical trials in neurodegenerative disease, their 
scientific underpinnings, and their implications for the future of treatment of patients 
suffering from neurodegenerative disease.Neuropsychiatric Disease and Treatment 2009:5 598
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Coenzyme Q10
CoQ10  (2,3  dimethoxy-5-methyl-6-decaprenyl 
benzoquinone), also known as ubiquinone, is a lipid-soluble 
quinone composed of a redox active quinone ring and hydro-
phobic tail (Figure 1).5–9 CoQ10, the predominant form of 
coenzyme Q in humans, contains 10 isoprenoid units in the 
tail, whereas the rodent form, coenzyme Q9 (CoQ9), has nine 
isoprenoid units. It is present in all organs, but is found in 
the highest concentrations in brain, heart, kidney, and liver 
tissue.3,6 It is synthesized endogenously, and approximately 
3–5 mg per day are consumed in the diet.9
CoQ10 participates in electron transfer in the mitochondrial 
oxidative respiratory chain, producing adenosine triphosphate 
(ATP).2,10,11 It accepts electrons from complexes I and II, 
and is also a coenzyme for complex III (Figure 2).12 When 
reduced, it is a powerful antioxidant that prevents oxidative 
damage by free radicals, including oxidation of lipids 
within the mitochondrial membrane.1,2 CoQ10 also serves 
as an antioxidant by activating and increasing expression 
of mitochondrial uncoupling proteins (UCPs), an effect 
which is antiapoptotic and leads to a reduction in free 
radical generation.10,12 There is also emerging evidence for 
pleiotropic effects. It has also been shown to inhibit MPTP 
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced 
interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), 
and nuclear factor-κB (NF-κB) expression, thus exerting 
an anti-inflammatory role,13 and more recently, gene 
expression profiling has revealed that CoQ10 influences 
the expression of hundreds of genes. It has been found in 
gene expression analysis and cell culture experiments to 
reduce the activity of inflammatory markers, suggesting it 
may have an anti-inflammatory effect via gene expression 
modification.14
Production, pharmacokinetics,  
and bioavailability
CoQ10 is available in several forms, including powder, 
suspension, oil solution, solubilized forms (All-Q and 
Q-Gel), as well as creams, tablets, wafers, and hard-shell 
or softgel capsules, all with different bioavailability. 
Recently a self-emulsifying drug delivery system (SEDDS) 
composed of oil and surfactant has been developed,15 as 
well as a new lipid-based formulation that self-assembles 
on contact with an aqueous phase into a colloid delivery 
system (VESIsorb, colloidal-Q10),16 both with the goal 
of improving bioavailability. It is available in more 
than 100 single-ingredient and combination-ingredient 
products.6,9 Additionally, idebenone, a short-chain analog 
that is less hydrophobic, has been produced (Figure 1).1 
Prices for CoQ10 softgels vary widely typically ranging from 
US$20–$60 for 60 to 120 100 mg capsules or for 30 400 mg 
capsules.
In a study by Kalenikova and colleagues, administration 
of 10 mg/kg of both powder and solubilized forms resulted 
in maximum plasma concentrations in 3–4 hours.17 
Using a lipid formulation and taking CoQ10 with food 
improves absorption.18 Over 24 hours, mean plasma concen-
trations of CoQ10 were significantly higher with the solu-
bilized form.17 In humans, orally dosed CoQ10 causes two 
peaks in serum levels occurring at 5–6 hours and 24 hours; 
the second peak is smaller and is thought to be a result of 
uptake and secretion by the liver. The elimination half-life 
is estimated to be between 30 and 50 hours. Studies have 
shown that a dose of 30 mg has negligible effects on plasma 
levels,18 while doses above 2,400 mg do not increase plasma 
levels beyond the plateau reached at that dose.19
Importantly, CoQ10 crosses the blood–brain barrier 
in animal studies. Matthews and colleagues demonstrated 
a 30%–40% increase in cerebral cortex mitochondrial 
concentrations of CoQ9 and CoQ10 at 12 months in mice,2 
and Smith and colleagues found brain levels of CoQ9 and 
CoQ10 to increase with oral supplementation in R6/2 mouse 
models of HD.8 Central nervous system penetration of oral 
CoQ10 in humans has not been studied.
Consequences of CoQ10 deficiency
CoQ10 deficiency is a rare disorder with variable phenotypic 
presentations including pure myopathy, myopathy with 
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Figure 1 Chemical structures of Coenzyme Q10 and its short-chain analog, 
idebenone.Neuropsychiatric Disease and Treatment 2009:5 599
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encephalopathy, cerebellar atrophy with ataxia, and 
infantile multisystem disease including encephalopathy 
and nephropathy.20,21 The most common is the ataxic 
variant.22 Huntsman and colleagues recently reported a 
case of hypotonia and infantile spasms which they hypoth-
esized to be a new phenotype of CoQ10 deficiency.23 
Response to CoQ10 supplementation in this disorder is 
variable, though it is the best response of any mitochondrial 
encephalomyopathy to CoQ10 supplementation.22 The 
causes of primary CoQ10 deficiency are yet to be com-
pletely elucidated. Nine genes are presumed to be involved 
in CoQ10 biosynthesis, and as of now, mutations in 
three genes have been shown to result in primary CoQ10 
deficiency: PDSS1, PDSS2, and COQ2.21 Duncan and 
colleagues found an autosomal recessive form of neonatal-
onset primary coenzyme Q10 deficiency resulting from 
a nonsense mutation in COQ9.24
In a recent study of the pathophysiology of CoQ10 
deficiency, fibroblasts from four patients were shown to 
have decreased activities of complexes I and II, complex III, 
and complex IV, reduced expression of mitochondrial 
proteins involved in oxidative phosphorylation, decreased 
mitochondrial membrane potential, increased production 
of reactive oxygen species, and reduced growth rate. 
These abnormalities reversed partially with coenzyme 
Q10 supplementation.25 Increased levels of lysosomal 
markers, enhanced expression of genes involved in 
autophagy, and findings on electron microscopy all 
provided evidence for massive degradation of dysfunctional 
mitochondria, which was eradicated with administration of 
antioxidants. Induced CoQ10 deficiency in cells genetically 
altered to lack autophagy resulted in apoptosis, indicating 
that the autophagy was likely protective.25
Mitochondrial dysfunction  
and neurodegenerative disease:  
A rationale for testing CoQ10
There are now multiple lines of evidence that strongly support 
mitochondrial dysfunction and oxidative stress as major 
contributors to pathogenesis of neurodegenerative diseases. 
These are well reviewed elsewhere, and some examples are 
briefly reviewed below.3,5,10,11,26–37
Increased markers of oxidative stress have been 
demonstrated in neurodegenerative disease, including 
elevated levels of 8-hydroxy-2’-deoxyguanosine (8OHdG) 
in Friedreich’s ataxia (FA), amyotrophic lateral sclerosis 
(ALS), and PD.32,35,36–40 Elevated protein carbonyl forma-
tion and oxidized nitric oxide products with decreased 
glutathione peroxidase activity have been shown in ALS 
patients, while increased levels of malondialdehyde in 
plasma and decreased aconitase activities in cardiac and 
skeletal muscle have been shown in FA.32,33,35,40,41 Evidence 
of mitochondrial dysfunction derives from animal models, 
studies of mitochondria from patients, postmortem 
pathology, identification of genetic defects in patients 
with neurodegenerative disease, and neuroimaging. For 
example, in PD, there is diminished complex I activity in 
the substantia nigra, platelets, and skeletal muscle,10,28,42 
and reduced activity of both complex I and II/III in platelet 
mitochondria.44,45 Moreover, the discovery of multiple PD 
genes whose function is linked to mitochondrial function 
or oxidative stress, although not proof, strongly supports 
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Figure 2 CoQ10 in the mitochondrial electron transport chain. Coenzyme Q10 is a component of the electron transport chain located within the inner mitochondrial 
membrane, required for oxidative phosphorylation leading to ATP generation. it accepts electrons from complexes i (NADH-ubiquinone oxidoreductase) and ii (succinate 
dehydrogenase) for transfer to complex iii (ubiquinol-cytochrome c reductase). idebenone is similarly involved in transfer of electrons from complex i to complex iii.Neuropsychiatric Disease and Treatment 2009:5 600
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a role for mitochondrial involvement in PD-associated 
neurodegeneration. In HD, there is evidence of deficiencies 
in complex I, II, and in some studies complex IV function, 
in multiple tissue types, including platelets, fibroblasts, and 
muscle cells, as well as brain.10,12,45,46 Postmortem deficiencies 
in key tricarboxylic acid (TCA) cycle enzymes, including 
pyruvate dehydrogenase, isocitrate dehydrogenase, and 
α-ketoglutarate dehydrogenase, have been described in AD, 
indicating impaired mitochondrial function.10,47,48 In addition, 
deficiencies in the activities of complexes I, III, and IV have 
been described in the cortex, platelets, and lymphocytes 
of patients with AD.3,10 In FA patients, decreased activities 
of complexes I, II, and III have been found in the cardiac and 
skeletal muscle, either via biopsy or postmortem.32,49,50
Coincident with aberrant mitochondrial function in PD, 
CoQ10 levels are significantly decreased in mitochondria 
from SN neurons and platelets in PD patients, and levels 
of CoQ10 have been shown to correlate with activity of 
complexes I and II/III.37 Decreased levels of CoQ10 in 
brain cortex relative to age-matched controls have also been 
demonstrated, though no reduction was found in the SN, 
cerebellum, or striatum.51 In serum, there is a reduction in the 
ratio of reduced to oxidized CoQ10 in PD37,52,53 and ALS.38,40 
However, serum total levels are no different from controls 
in PD,54 HD,55 and ALS.40,56
Evidence of neuroprotective  
effects of coenzyme Q10 in vitro
CoQ10 has been studied in multiple in vitro models of 
neuronal toxicity, with results that overall have supported 
a neuroprotective effect. In striatal slice cultures of mice, 
CoQ10 decreases 1-methyl-4-phenylpyridinium(MPP+)-
induced inhibition of complexes I and II, tyrosine hydroxylase, 
and hexokinase.30 CoQ10 protects against rotenone-induced 
mitochondrial dysfunction and cell death in rat mesencephalic 
neurons and against iron-induced apoptosis in dopaminergic 
neurons.57,58 In neuronal cell models of oxidative stress, 
pre-treatment with CoQ10 preserves mitochondrial 
membrane potential and reduces generation of reactive 
oxygen species.59 Importantly, CoQ10 also protects human 
neuroblastoma (SHSY-5Y) cells against paraquat-induced 
mitochondrial dysfunction as well as against β-amyloid 
toxicity.60,61 Complex I and IV deficiencies in PD skin 
fibroblasts are improved by CoQ10.62 Administration of 
CoQ10 has also inhibited NMDA-receptor-induced cell 
death to a greater degree in cultured medium spiny projection 
neurons of YAC46 mice, transgenic models of HD, relative 
to those of wild type mice.63
Coenzyme Q10 has also been found to exert effects on 
α-synuclein and β-amyloid fibrils in vitro, possibly due to 
binding with hydrophobic and antioxidant motifs.64,65 Along 
with other antioxidants, it destabilizes pre-formed β-amyloid 
fibrils in vitro, and inhibits formation and extension of 
β-amyloid fibrils.65 Similarly, it dose-dependently inhibits 
formation of α-synuclein fibrils, and destabilizes pre-formed 
α-synuclein fibrils.64
With regard to FA, succinate-reduced CoQ10 has been 
shown to protect membrane lipids and complex II against iron 
injury in human heart homogenate in vitro.7 Mitochondria-
targeted CoQ10, MitoQ, prevented cell death in fibroblasts 
of FA patients which were treated with buthionine sulfoxime 
(BSO), an inhibitor of glutathione biosynthesis that causes 
death of FA fibroblasts but not of those of controls.66
CoQ10 effects in healthy  
animals and animal models  
of neurodegenerative disease
Studies of the effects of CoQ10 have been performed on 
healthy animals as well as animal models of neurodegen-
erative disease, and the major studies are summarized in 
Table 1.
In healthy animals, oral administration of CoQ10 increases 
CoQ10 levels in the brain of older animals, whereas 
there is no effect on CoQ10 levels in young animals. 
In one study, feeding with 200 mg/kg of CoQ10 daily for 
1–2 months resulted in 30%–40% increases in cerebral 
cortex mitochondrial concentrations of CoQ (CoQ10 more 
than CoQ9) at 12 months; these increased levels were 
comparable to those of healthy 2–3-month-old rats. Similar 
feeding for one month at 24 months of age resulted in 10% 
increases in cerebral levels.2 In this same study, in 10 animals 
administered 3-nitropropionic acid, striatal lesions were 
attenuated by 90% in the CoQ10 group relative to the 
placebo group.2
Oral administration of CoQ10 for 7–10 days prior to 
injection of malonate in rats dose-dependently prevented 
malonate-induced ATP depletion at three hours, attenuated 
striatal lesions, and with nicotinamide prevented malonate-
induced increases in lactate in vivo as assessed by MRS.67 
Beal et al demonstrated that in 12-month-old mice pre-treated 
with CoQ10 for 4 weeks, CoQ10 protects against dopamine 
depletion and loss of tyrosine hydroxylase immunostained 
neurons induced by MPTP.27 Cleren and colleagues showed 
that in a chronic MPTP model, oral administration of CoQ10 
protected against dopamine depletion, loss of TH-IR neurons 
in the SN, and development of α-synuclein aggregates.68 Neuropsychiatric Disease and Treatment 2009:5 601
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Table 1 Studies of effects of CoQ10 on healthy animals and animal models of neurodegenerative disease
Model Dose Effect Ref
Healthy rats 200 mg/kg daily × 1–2 months •    30%–40% increase in 
cerebral mitochondrial CoQ 
concentrations
Matthews2
Huntington’s models
Malonate 200 mg/kg daily × 1–2 months •  Prevented depletion of ATP  
• Attenuated striatal lesions  
•   with nicotinamide, prevented 
increase in lactate on MrS
Beal29
3-NP 200 mg/kg daily × 1–2 months •   Attenuation of striatal lesions 
by 90%
Matthews2
N171–82Q mice 500 mg/kg/day •  Diminished motor symptoms
•  No effect on survival 
•    effect augmented by 
remacimide
Ferrante45
r6/r2 and N171–82Q 
transgenic mice
CoQ10 400 mg/kg/day ± 
remacemide 14 mg/kg/day
•  Prolonged survival (additive)
•    Delayed motor deficits, weight 
loss, cerebral atrophy, and 
neuronal intranuclear inclu-
sions
Ferrante45
r6/r2 transgenic mice 1,000 to 20,000 mg/kg/day •  Prolonged survival 
•    improved motor performance
•  reduced weight loss
•    Decrease in cerebral and 
striatal neuron atrophy, Htt 
aggregate accumulation
Smith8
r6/2 transgenic mice CoQ10 (0.2%) and 
minocycline 5 mg/kg/day
•  extended survival  
•  improved motor performance
•   Amerliorated weight loss and 
Htt aggregation (CoQ domi-
nant effect)
Stack71
3-NP CoQ10 (1%) and  
creatine (2%) × two weeks
•    reduced striatal lesion volumes 
(additive)
Yang72
r6/2 transgenic mice CoQ10 (1%) and  
creatine (2%) × 9–11 weeks
•    improved motor performance 
(additive)
•  extended survival (additive)
Yang72
Parkinson’s models
MPTP CoQ10 200 mg/kg/day ×  
five weeks
Protected against:  
•  Striatal dopamine depletion
•    Loss of TH-ir neurons in the 
SNpc
Beal27
MPTP CoQ10 1600 mg/kg × 
3.5 months
Protected against: 
•  Dopamine depletion 
•    Loss of TH-ir neurons in the 
SNpc 
•    Development of α-synuclein 
aggregates in SNpc
Cleren68
MPTP CoQ10 (1%) and  
creatine (2%) × 5 weeks
Protected against: 
•    Dopamine depletion in the 
striatum (additive)
•    Loss of tyrosine hydroxylase 
neurons in SNpc (additive)
•  Lipid peroxidation 
•    α-synuclein aggregates in SNpc
Yang72
(Continued)Neuropsychiatric Disease and Treatment 2009:5 602
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Table 1 (Continued)
Model Dose Effect Ref
ALS models
G93 A SOD1 transgenic  
mouse
200 mg/kg daily from day 50  
until end-stage disease
•    Significantly increased median  
survival by 4.4% (six days)
Matthews2
Alzheimer models
Aged APP, PS1, APP/PS1  
transgenic mice
2,400 mg/kg/day × 60 days •   Attenuated brain atrophy  
as assessed by Mri in vivo
Li74
Aged PS1 transgenic  
mouse
1,200 mg/day × 60 days •    Partially reduced Aβ overproduction 
and intracellular cortical deposits
•   Attenuation of elevated malondialdehyde 
levels and downregulated SOD
Yang73
TG19959 mice 0.4% in diet •  Protected against plaques 
•    Protected against memory loss  
as assessed by Morris water maze task
Kipiani75
Abbreviations: mg, milligram; kg, kilogram; CoQ, coenzyme Q; CoQ10, coenzyme Q10; ATP, adenosine triphosphate; MrS, magnetic resonance spectroscopy; 3-NP, 3-nitroproprionic 
acid; Htt, huntingtin; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine;   TH-ir, tyrosine hydroxylase-immunoreactive; SNpc, substantia nigra pars compacta; SOD, superoxide 
dismutase;   Aβ, β-amyloid;   APP, amyloid precursor protein; PS1, presenilin 1; Mri, magnetic resonance imaging.
Rotenone-induced complex I inhibition in mice is attenuated 
by CoQ10 supplementation.13
In R6/2 and N171–82Q transgenic mouse models of HD, 
oral administration of coenzyme Q10 significantly prolonged 
survival and delayed motor deficits, weight loss, cerebral 
atrophy, and appearance of neuronal intranuclear inclusions.45 
Brain levels of CoQ10 and CoQ9 were significantly lower in 
R6/2 mice relative to wild type mice, and oral supplementation 
with CoQ10 increased brain levels of CoQ9, CoQ10, and 
ATP, and reduced 8-hydroxy-2-deoxyguanosine levels. 
Mice which were administered high-dose CoQ10 (1000 to 
20,000 mg per kg per day) from age 28 days displayed 
prolonged survival, improved motor performance, reduced 
weight loss, decreased cerebral and striatal atrophy, and 
reduced huntingtin aggregate accumulation.8 In a study of 
N171-82Q mice, motor symptoms were diminished by oral 
CoQ10 500 mg/kg/day beginning at the age of eight weeks, 
with peak effect at 13 weeks. No effect was observed on 
survival, but this parameter was confounded by a chow 
formulation that cut short the life expectancy of all animals.69,70 
Combination therapy with remacemide augmented the motor 
performance and survival benefit, and attenuated the loss of 
striatal neurons.45 A study of the combination of minocycline 
and CoQ10 therapy in R6/2 mice yielded similar results; 
while the combination extended survival and improved motor 
performance greater than either agent alone, CoQ10 was 
found to play the dominant role in ameliorating weight loss 
and huntingtin aggregation.71 Similarly, in a transgenic mouse 
model of familial ALS that overexpresses Cu/Zn superoxide 
dismutase (SOD1) with the G93 A mutation, treatment with 
CoQ10 200 mg/kg/day, started at 50 days of age, significantly 
increased mean life span by 4.4% (six days).2
A  recent  study  aimed  to  determine  whether 
co-administration of creatine and coenzyme Q10 would 
have additive effects in animal models of neurodegenerative 
disease.72 Additive neuroprotective effects were observed in 
the MPTP model against dopamine depletion in the striatum 
and loss of tyrosine hydroxylase neurons in the substantia 
nigra pars compacta (SNpc), in the 3-NP-treated rats with 
reduction of striatal lesion volumes, and in the transgenic 
R6/2 HD mice with improved motor performance and 
extended survival. In addition, the combination treatment 
resulted in a significant reduction of lipid peroxidation and 
alpha-synuclein accumulation in the SNpc in MPTP-treated 
mice, and reduction of lipid peroxidation and DNA oxidative 
damage in the striatum in the 3-NP rat model.72
In aged transgenic mice overexpressing Alzheimer 
presenilin 1-L235P mutation, treatment with CoQ10 1,200 mg 
per day for 60 days partially reduced A beta overproduction 
and intracellular A beta cortical deposits. In addition, 
increased levels of malondialdehyde and downregulation of 
SOD, both markers of oxidative stress seen in the transgenic 
mice, were ameliorated by CoQ10 treatment.73 Supplemental 
CoQ10 was also found to attenuate brain atrophy at 60 days, 
as assessed by MRI in vivo, in aged transgenic mice with 
amyloid precursor protein (APP) mutations. Single transgenic 
APP and presenilin 1 (PS1) mice as well as double transgenic 
APP/PS1 mice were treated with 2,400 mg/kg/day or placebo. 
The treated mice, including wild-type, exhibited significantly 
less atrophy in the hemispheres and hippocampus than those Neuropsychiatric Disease and Treatment 2009:5 603
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receiving placebo.74 A study by Kipiani and colleagues, 
currently in press, found that administration of CoQ10 in 
TG19959 transgenic mice, models of AD, conferred protection 
against plaques and memory loss, as assessed by the Morris 
water maze task.75
Activation of uncoupling proteins by CoQ10 has been 
associated with neuroprotection against MPTP toxicity in 
the substantia nigra of primates.10,11,76
Clinical studies of CoQ10 effects  
in neurodegenerative disease
Given the encouraging results from preclinical studies, 
extensive efforts have been initiated in order to translate poten-
tial benefits into the clinical arena. These are summarized in 
Table 2, and are discussed below.
Parkinson disease (PD)
One of the first studies of the effects of CoQ10 in PD was 
an open-label trial in 10 subjects, using 200 mg of CoQ10 
daily for three months, that found no significant effect on 
Unified Parkinson’s Disease Rating Scale (UPDRS) motor 
scores and motor testing.4 An open-label phase I trial of one 
month of daily CoQ10 in 15 subjects with PD was conducted 
to ascertain safety, tolerability, and effect on plasma levels. 
While the plasma levels were found to increase with doses of 
400, 600, and 800 mg per day, and the therapy was very well 
tolerated, no change in UPDRS scores or video examinations 
was observed. Interestingly, a trend towards increased 
mitochondrial complex I activity was noted.77
A pivotal randomized, double-blind, placebo controlled, 
multicenter phase II study of CoQ10 in 80 early untreated 
PD patients was published in 2002.78 This study, known 
as QE2 and conducted by Shults and colleagues, tested 
doses of 300, 600, and 1200 mg daily, for up to 16 months 
or until disability requiring dopaminergic therapy had 
developed. Subjects also received 1,200 IU vitamin E per 
day. Subjects were well matched for gender, age, severity 
of PD (using UPDRS scores, Hoehn and Yahr Scale scores, 
and timed tapping scores), disability (Schwab and England 
Scale score), and intellectual function (Mini-Mental State 
Examination [MMSE]), at baseline. The primary endpoint 
was the change in total UPDRS score from baseline to final 
visit.CoQ10 supplementation was associated with up to 
44% less functional decline in PD subjects (P = 0.09), most 
pronounced in part II of the UPDRS (ADLs). Evaluation 
at one month revealed no significant UPDRS difference, 
though there was benefit in UPDRS ADL scores. By eight 
months, differences between the groups were apparent, 
with those receiving 1,200 mg daily showing the greatest 
benefit. The secondary endpoint assessed each treatment 
group compared with placebo, and only the group receiving 
1,200 mg per day had a benefit that met significance 
(P = 0.04). Using the Schwab and England scale change as an 
endpoint, which measures independence, also demonstrated 
a benefit in those receiving CoQ10. However, administration 
of CoQ10 did not significantly increase time to disability 
requiring dopaminergic therapy. Of note, platelets from 
subjects assigned to CoQ10 arms had increased activity of 
complexes I, II, and III compared with patients receiving 
placebo (P = 0.04). Moreover, an assay of NADH to cyto-
chrome-c reductase activity showed a significant increase in 
the patients treated with 1,200 mg CoQ10.78
One question arising from the QE2 study was whether 
higher doses of CoQ10 could provide a greater degree of 
benefit. An open label study of 17 patients was conducted to 
assess tolerability of high doses of CoQ10. Patients received 
escalating doses of CoQ10 from 1,200 mg to 3,000 mg per 
day over eight weeks.19 Thirteen of the 17 patients tolerated 
the maximum dose, but plasma levels reached a plateau 
at 2,400 mg per day, suggesting futility of studying doses 
higher than this. Video examinations showed no change.19 
Using this data, the NINDS NET-PD investigators conducted 
a randomized, double-blind, futility trial of 2,400 mg 
of CoQ10 in early untreated PD. Placebo data from the 
DATATOP trial were used to establish the futility criteria, 
which were not met by CoQ10, indicating the need for further 
studies.79 There have, however, been questions surrounding 
the applicability of these historical placebo data, given 
that practice styles and patient expectations have altered, 
and this has made interpretation of the NET-PD data for 
CoQ10 more difficult. Finally, a NINDS-funded phase III, 
multicenter, randomized, placebo-controlled, double blind 
trial (NCT00740714, known as QE3) of CoQ10 at doses of 
1200 mg and 2400 mg daily in combination with 1200 IU 
daily vitamin E, is enrolling a target of 600 subjects with 
early, unmedicated PD in the USA and Canada, in an effort 
to confirm and extend results from the QE2 trial.
An important point is that if the designs of the QE2 and 
QE3 clinical trials are to provide data bearing upon a neu-
roprotective effect, CoQ10 must be free of any symptomatic 
benefit that would cloud interpretation. In order to determine 
whether the effects of CoQ10 may be symptomatic rather 
than neuroprotective, Storch and colleagues conducted a 
multicenter, randomized, placebo-controlled, double-blind 
study of 106 PD patients, treated with CoQ10 300 mg/day 
for three months.80 All patients were within Hoehn and Yahr Neuropsychiatric Disease and Treatment 2009:5 604
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Table 2 Clinical trials of CoQ10 in neurodegenerative disease
Study type n Dose Effect P value Ref
Parkinson’s
Open label 10 200 mg/day × three 
months
•    No significant effect on 
UPDrS and motor testing
– Strijks4
Open label Phase i 15 400, 600, and 800 mg/day × 
one month
•    No change in UPDrS or video
•    increase in plasma CoQ10 
levels relative to controls
•   Trend towards increased  
complex i activity
0.05 Shults77
Phase ii (Qe2) randomized,   
double-blind,  
placebo-controlled
80 300, 600, and 1200 mg/day, 
up to 16 months with 
vitamin e 1200 iU/day
•    44% less functional decline, 
most pronounced in ADLs  
(part ii UPDrS)
•    Met significance in 1,200 mg 
dose group (P = 0.04)
•    increased activity of electron 
transport chain complexes  
i & iii
•    Did not decrease time to 
levodopa
0.09  
 
0.04 
 
0.04
Shults78
Placebo-controlled,  
double-blind
28 360 mg/day × four weeks •    Mild but significant 
improvement in UPDrS
•    No improvement of motor 
symptoms
•    Significant improvement in 
performance on color visual 
testing
0.01 
 
 
 
0.008
Muller81
Open label 12 1,000 mg/day × three 
months, then 1,500 mg/day 
× three months
•    Minor but statistically 
significant beneficial effect 
on motor performance with 
1,500 mg versus placebo
0.004 Horstink82
randomized, placebo-
controlled, double-blind, 
Levodopa-stratified
106 100 mg three times/day × 
three months
•    No significant change in  
UPDrS – no symptomatic 
effects
– Storch80
Open label 17 1,200 to 3,000 mg/day over 
eight weeks
•    Plateau of plasma levels at 
2,400 mg/day
•    No change in video exam or 
UPDrS
– Shults19
randomized, Double-blind 71 2,400 mg/day •  Did not meet futility criteria 0.48 NiNDS-PeT79
Huntington’s
Open label 10 600–1,200 mg/day × six 
months
•    No significant effect on clinical 
scores
– Feigin83
Open label 18 360 mg/day for 2 months •   Ameliorated cerebral cortex 
lactate levels seen on MrS
0.001 Koroshetz84
randomized,  
placebo-controlled,  
double-blind (CAre-HD)
174 300 mg twice 
daily, × 30 months, also in 
combination with remacimide
•   Trend toward lessened decline in 
total functional capacity of unified 
HD rating scale, after one year
0.15 HSG86
Friedreich’s ataxia
Open label 10 400 mg/day with vitamin e 
2,100 iU/day, × 47 months
•    No improvement or 
progression in neurologic 
evaluation at six months
•   At 47 months, compared to 
cross-sectional data, slowed 
progression of total iCArS and 
kinetic scores for seven patients
0.01 Hart89
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Table 2 (Continued)
Study type n Dose Effect P value Ref
Double-blind, randomized 50 30 mg/day alone vs  
600 mg/day with vitamin e 
2100 iU
•    49% with improved iCArS 
compared to cross-sectional 
data
– Cooper31
ALS
Open label, placebo-
controlled
31 Up to 3000 mg/day  
for eight months
•    Plateau at 2400 mg/day
•    No adverse effects 
at 3,000 mg/day
Ferrante92
Phase ii trial Futility study 185 1,800 mg/day vs 
2,700 mg/day for  
nine months
•    No significant differences 
between CoQ10 and placebo
•    Insufficient promise to warrant 
phase iii testing
– Kaufmann93
Progressive supranuclear  
palsy
Phase ii trial 21 5 mg/kg/day × six weeks •    ratio of high-energy to 
low-energy phosphates 
increased in occipital lobe, 
trend in basal ganglia
•    Significant mild improvement 
in PSP rating scale and frontal 
assessment battery
Stamelou91
Abbreviations: mg, milligrams; kg, kilograms; UPDRS, Unified Parkinson’s Disease Rating Scale; CoQ10, coenzyme Q10; IU, international units;   ADLs, activities of daily living; 
NiNDS, National institute of Neurological Disorders and Stroke; NeT-PD, Neuroprotection e×ploratory  Trials in Parkinson’s Disease; HD, Huntington’s disease; HSG, Huntington’s 
Study Group; iCArS, international Cooperative Ata×ia rating Scale; PSP, progressive supranuclear palsy; MrS,.
stages II–III, without motor complications, and were stratified 
by treatment with levodopa. No significant change in UPDRS 
scores, the primary endpoint, was observed, though serum 
CoQ10 levels were significantly elevated in all patients to a 
degree similar to levels attained with 1,200 mg in the phase II 
trial reported by Shults and colleagues. The study authors 
concluded that adjunctive CoQ10 in mid-stage PD does 
not exert a symptomatic effect.80 Other small studies have 
suggested potential benefit, but these have been minor and 
of unclear significance.81,82
Huntington’s disease (HD)
As in PD, there have been considerable efforts to determine 
whether CoQ10 could provide a neuroprotective effect. Ten 
subjects with HD were studied in a six-month open-label trial 
of tolerability and efficacy of CoQ10. Doses ranged from 600 
to 1,200 mg per day, with no significant effect on clinical 
scores at three or six months.83 In addition to clinical endpoints, 
proton magnetic resonance spectroscopy (1H-MRS) has been 
used in HD as a marker of CoQ10 effects. Increased lactate 
concentrations in the cerebral cortex and basal ganglia, as mea-
sured by 1H-MRS, have been shown to decrease with CoQ10 
administration, and subsequently elevate upon withdrawal 
of treatment.84 This finding supports the predicted metabolic 
effect of oral CoQ10 in cerebral tissue, and is suggestive of 
an effect upon mitochondrial metabolism.
In 2001 the Huntington Study Group published the 
CARE-HD trial, a randomized, placebo-controlled, 
multicenter, double-blind trial of CoQ10 300 mg twice daily 
in 174 subjects with early HD.85 This therapy was compared 
with remacemide 600 mg daily, combination therapy, or 
placebo. Patients were followed every four to five months 
for 30 months, at which point no significant reduction in 
functional decline was observed with any therapy. However, 
CoQ10 treatment resulted in a trend toward less decline in 
total functional capacity of the Unified HD Rating Scale 
(UHDRS), the primary endpoint of the trial. This benefit was 
observed only after a year of treatment, thus a symptomatic 
effect of CoQ10 is unlikely to explain it. Interestingly, 
secondary analyses of functional and cognitive decline 
showed significant slowing with CoQ10 treatment. While 
this study was powered to detect 35%–40% reduction in 
decline, detection of smaller benefits and even confirmation 
of the effects seen in this study would require a prohibitively 
large sample size.12,46,85
Pre-2CARE was a small, pilot, open-label, dose-ranging 
study in 20 HD and six healthy subjects.86 CoQ10 was admin-
istered at doses of 1,200 mg daily for one month, 2,400 mg 
daily for the next month, and then 3,600 mg daily continued 
for 12 weeks. An ongoing large phase III clinical trial of 
high dose CoQ10 in HD (2CARE – NCT00608881) is now 
testing these potential effects. This trial has an estimated Neuropsychiatric Disease and Treatment 2009:5 606
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enrollment of 608 patients, and will compare the effects of 
CoQ10 2400 mg/day with placebo for five years on change 
in total functional capacity.
Friedreich’s ataxia (FA)
Interestingly, CoQ10 and its analog idebenone were studied 
in FA using cardiac prior to neurologic outcomes. As early as 
1999 a 31%–36% reduction in septal thickness and 8%–20% 
reduction of left ventricle posterior wall was measured in 
three subjects with FA who were administered idebenone for 
4–9 months.7 This finding was replicated in a larger cohort, 
in which 20% or greater reduction in left ventricular mass 
was demonstrated by echocardiogram in 17 out of 38 subjects 
given idebenone.87
Lodi and colleagues conducted a prospective, open-label 
study of 10 subjects with FA which evaluated both cardiac 
and neurologic parameters at three months, six months, and 
47 months of treatment with CoQ10.88 Serum CoQ10 levels 
increased by 2.3- to 7.4-fold in all patients. This revealed a 
significant increase in maximum rate of ATP production in 
skeletal muscle at three and six months, but no improvement 
of echocardiogram findings or neurologic evaluation, with 
CoQ10 400 mg per day and vitamin E 2100 IU per day. 
Neurologic evaluation of cerebellar signs using the Inter-
national Cooperative Ataxia Rating Scale (ICARS) showed 
no progression, but no improvement either.49,88 Four years 
later, ICARS scores obtained on follow-up were compared 
with those of 77 subjects with FA stratified by GAA1 repeat 
size, to serve as controls.89 CoQ10 administration resulted 
in slowed progression of the total ICARS score and kinetic 
scores for seven subjects, but no difference in progression 
of posture, gait, and hand dexterity scores. Improvement of 
cardiac and skeletal muscle bioenergetics found in the first 
study persisted over 47 months.50,89
A double-blind, randomized, but not placebo-controlled 
study of CoQ10 examined low versus high dose CoQ10 
(30 mg versus 600 mg) in 50 FA patients.31 The primary 
end-point was change in ICARS over two years, and again, 
cross-sectional data was used as a control group in lieu 
of a placebo arm. Serum CoQ10 levels were decreased at 
baseline in FA patients, and were significantly increased 
in both groups (3.4-fold in the low-dose group, 12.2-fold 
in the high-dose group). While there was no difference in 
rate of deterioration between the two treatment groups (the 
primary endpoint), 49% of all subjects receiving CoQ10 had 
improved ICARS scores when compared to cross-sectional 
data. Of note, this subgroup had significantly lower baseline 
serum CoQ10 levels.31
Recently Rinaldi and colleagues published a retrospective 
analysis of 35 patients with FA given idebenone 5 mg/kg/day 
for up to five years. Patients without left ventricular hyper-
tension (LVH) prior to treatment had an increase in size of 
the interventricular septum and posterior wall thickness, 
while those with LVH prior to treatment had no change. 
The neurologic conditions of patients in both groups 
deteriorated.90
Progressive supranuclear palsy (PSP)
The clinical effects of CoQ10 in PSP, a rare disorder, have not 
yet been well-defined. However, a randomized, double-blind, 
placebo-controlled, phase II trial of CoQ10 5 mg/kg/day in 
21 probable PSP patients (stage  III) for six weeks made 
use of MRS as a noninvasive measure of indices of metabolic 
function. Subjects receiving CoQ10 demonstrated decreased 
concentration of low-energy phosphates and increased ratios 
of high-energy to low-energy phosphates, as assessed by 
(31)P-MRS and (1)H-MRS, reaching significance in the 
occipital lobes and showing a trend in the basal ganglia. The 
PSP rating scale and frontal assessment battery improved 
slightly but significantly. Clinical assessments using 
UPDRS III, Hoehn and Yahr stage, MMSE, and Montgomery 
Asberg Depression Scale showed no change.91 Currently a 
phase III trial of CoQ10 in PSP patients is recruiting, with 
a goal of 60 patients undergoing treatment with CoQ10 for 
one year (NCT00382824).
Amyotrophic lateral sclerosis (ALS)
An open-label, placebo-controlled, dose escalation trial of 
CoQ10 was performed in 31 subjects with ALS, for the 
purpose of assessing safety and tolerability. Subjects were 
given doses of CoQ10 up to 3,000 mg/day for eight months. 
There was no significant difference in adverse effects 
between the treatment groups or among treatment groups. 
The serum level reached a plateau at the 2,400 mg/day 
dosage, indicating that further studies need not exceed this 
dosage, though no increase in side effects were observed at 
3,000 mg/day.92 A phase II trial of CoQ10 1,800 mg daily or 
2,700 mg daily versus placebo in 185 ALS patients, with an 
adaptive design incorporating a futility test, found insufficient 
evidence to support a phase III trial. Using prespecified 
secondary analyses, no significant difference was found 
between CoQ10 2,700 mg daily and placebo.93
Alzheimer disease (AD)
No clinical trials have been performed using CoQ10 in AD. 
However, multiple trials of idebenone in AD were conducted Neuropsychiatric Disease and Treatment 2009:5 607
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in the 1990s, many demonstrating clinical benefit. In 1992, 
Senin and colleagues published a multicenter, double-
blind, placebo-controlled trial of idebenone 45 mg twice 
daily for four months in 102 elderly AD patients, finding 
a statistically significant benefit in memory, attention, 
and behavior.94 Bergamasco and colleagues conducted a 
multicenter, randomized, placebo-controlled, double-blind 
trial of idebenone treatment for 90 days in 92 patients, 
followed by optional long-term treatment, and found it to 
be effective on memory, attention, and orientation, and to 
slow the progressive worsening of the disease.95 In 1997, 
Weyer and colleagues randomized 300 patients to idebenone 
30 mg TID, 90 mg TID, or placebo for six months, resulting 
in significant superiority of idebenone 90 mg TID in clinical 
global response improvement, and the AD Assessment Scale 
cognitive (ADAS-Cog) and noncognitive (ADAS-Noncog) 
scores.96 Gutzmann conducted a two-year trial idebenone 
treatment for two years versus placebo for one year followed 
by one year of idebenone treatment, using the total ADAS 
score as a primary endpoint. He found that those started 
earlier on idebenone had superior efficacy than those started 
after one year of placebo, indicating a disease-modifying 
rather than symptomatic effect.97 However, in 2003, Thal 
and colleagues published a one-year, multicenter, double-
blind, placebo-controlled, randomized trial of idebenone 
120, 240, or 360 mg TID in 536 AD patients, with primary 
endpoint of ADAS-Cog and Clinical Global Impression 
of Change (CGIC) scores, demonstrating no significant 
difference in primary or secondary outcomes between the 
treatment groups.98
Safety and tolerability
In all of the studies mentioned above, most notably the 
study of up to 3,000 mg/day in ALS patients by Ferrante and 
colleagues, no serious adverse effects have been reported, 
even at the highest doses.92 In the NET-PD study of CoQ10, 
CoQ10 was generally well tolerated. It was terminated early 
in four versus seven subjects in the placebo (Vitamin E alone) 
arm. Laboratory testing, including serum chemistry, blood 
counts, and urinalysis, did not differ between groups. There 
were four serious adverse events (SAEs) in the CoQ10 arm 
(diverticulosis exacerbation; gall bladder disorder; increased 
cough; recurrent kidney stone) versus six in the placebo 
arm (syncope; atrial fibrillation; attempted suicide; serious 
fall; elective urological surgery; TIA). None of these were 
thought to be related to the study intervention. The most 
common nongastrointestinal adverse events (AEs) in the 
CoQ10 group were headache (14% vs 14% placebo), upper 
respiratory infection (13% vs 14% placebo), and anxiety 
(13% vs 14% placebo). Gastrointestinal side-effects were 
nausea (11% vs 13% placebo), diarrhea (7% vs 3% placebo), 
gastro-esophageal reflux (7% vs 4% placebo) and heartburn 
(6% vs 3%). In Pre-2CARE, an open-label dose-ranging study 
in 20 HD and eight healthy subjects using escalating doses 
over two months up to 3,600 mg for 12 weeks, six subjects 
withdrew prematurely (GI symptoms, three; worsened HD 
symptoms, two; fall, one) and five did not reach the 3,600 mg 
dose.86 Gastrointestinal complaints were the most frequently 
reported AEs. In an eight-month tolerability study, 31 ALS 
subjects were given COQ10 in escalating doses over four 
months up to 3,000 mg daily for another five months.92 Of the 
initial 31 enrollees, 24 completed the study at the maximal 
dose and one at a sub-maximal dose. No difference in plasma 
CoQ10 levels was detected in increases from 2,400 mg to 
3000 mg daily. Headache, rash, urinary tract infection, and 
peripheral edema were seen in 16.1%, and abdominal pain, 
constipation, diarrhea, arthralgia, and infection in 12.9%. 
Of nine SAE’s, four occurred on CoQ10 but were judged 
unlikely to be related (myocardial infarction, dysphagia, 
hospice respite stay, respiratory disorder). Vital signs and 
laboratory tests were not significantly different (blood count, 
serum biochemistry, liver function tests, creatine kinase, 
urinalysis).
Overall, therefore, the most common side effect is mild 
gastrointestinal discomfort from CoQ10, and this occurs in 
less than 1%.6,9 Isolated case studies regarding CoQ10 have 
reported decreased anticoagulant effect of warfarin, but this 
effect has not been confirmed in prospective studies.6 A recent 
trial of CoQ10 200 mg daily in pregnant women at risk for 
pre-eclampsia reported no adverse effects.99 Currently, no 
absolute contraindications to the use of CoQ10 exist.
Conclusion
There is an urgent need to identify agents that will provide 
neuroprotection and slow disease progression in neurode-
generative diseases that have an enormous collective impact 
on our society. Detailed and extensive pre-clinical studies 
have strongly supported CoQ10 as such a potential agent. 
This review outlines results from clinical trials that are 
encouraging, but have not yet clearly demonstrated its effect. 
One issue that the studies raise is the barrier to translating 
promising animal studies into human neurodegenerative 
disease. Improvements in animal models and development of 
relevant biomarkers to track disease progression and identify 
presymptomatic patients are ways in which this barrier is 
currently being addressed. It is also possible that response to Neuropsychiatric Disease and Treatment 2009:5 608
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CoQ10 may vary not only among different neurodegenerative 
diseases but also among subtypes of these diseases. Small 
sample sizes make it difficult to perform any meaningful 
regression analyses of the existing trials to stratify response 
by subtype. Future studies that will hopefully have larger 
sample sizes should aim to assess responses within subgroups 
of neurodegenerative diseases, defined either by phenotype, 
endophenotype, or genotype. Finally, the therapeutic range 
of CoQ10 in neurodegenerative disease may be much higher 
than the doses that have been studied, especially given that 
the central nervous system bioavailability of oral CoQ10 in 
humans is unknown. Indeed, the doses used in the most 
promising animal studies have been in the tens of thousands 
of milligrams per day. Ferrante’s dose escalation trial, which 
demonstrated a serum plateau of CoQ10 levels at 2,400 mg 
per day, suggests that such high doses are not necessary, but 
studies using greater than 2,000 mg are needed. The phase III 
trial of CoQ10 in PD, QE3, is currently enrolling, and will 
shed some light on the question of a therapeutic range, with 
doses of 1,200 mg versus 2,400 mg of CoQ10.
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